Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company's advanced-stage product candidate is Roclatan, a once-daily eye drop to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone919-237-5300
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees160
OptionableOptionable
Aerie Pharmaceuticals (NASDAQ:AERI) Frequently Asked Questions
What is Aerie Pharmaceuticals' stock symbol?
Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."
How were Aerie Pharmaceuticals' earnings last quarter?
Aerie Pharmaceuticals Inc (NASDAQ:AERI) released its quarterly earnings results on Wednesday, August, 8th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.98) by $0.16. The firm earned $2.42 million during the quarter, compared to analyst estimates of $1.16 million. View Aerie Pharmaceuticals' Earnings History.
When is Aerie Pharmaceuticals' next earnings date?
What price target have analysts set for AERI?
11 Wall Street analysts have issued twelve-month target prices for Aerie Pharmaceuticals' shares. Their predictions range from $64.00 to $105.00. On average, they expect Aerie Pharmaceuticals' stock price to reach $79.20 in the next twelve months. This suggests a possible upside of 102.9% from the stock's current price. View Analyst Price Targets for Aerie Pharmaceuticals.
What is the consensus analysts' recommendation for Aerie Pharmaceuticals?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerie Pharmaceuticals in the last year. There are currently 1 sell rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aerie Pharmaceuticals.
What are Wall Street analysts saying about Aerie Pharmaceuticals stock?
Here are some recent quotes from research analysts about Aerie Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "The FDA approval of Aerie’s lead drug, Rhopressa is a significant boost for the company. Aerie is also evaluating Rocklatan, a once-daily, quadruple-action fixed-dose combination of Rhopressa and Xalatan (latanoprost). The PDUFA (Prescription Drug User Fee Act) goal date for the completion of the FDA’s review of the Rocklatan NDA is set for Mar 14, 2019. Loss estimates have widened ahead of the Q4 earnings and the company has a negative earnings surprise in the recent quarters. While the glaucoma market holds potential, Aerie faces stiff competition from established branded and generic pharmaceutical companies, such as Novartis’ Simbrinza and Travtan, and Allergan’s Lumigan, as well as other smaller biotechnology and pharmaceutical companies. Shares have underperformed the industry in the past twelve months." (2/8/2019)
- 2. Mizuho analysts commented, "We are including weekly IQVIA Scripts for Rhopressa below. For the week ended 02/01/2019, Rhopressa TRx increased +2.6% to 5,283 from 5,150 the prior week; and Rhopressa NRx increased +1.2% to 2,330 from 2,302 the prior week." (2/8/2019)
- 3. Cantor Fitzgerald analysts commented, "We rate Aerie Pharmaceuticals Overweight. AERI commercializes and develops once- daily eye drops Rhopressa and Roclatan, respectively, for glaucoma. Rhopressa is the first novel drug in a market that has not seen innovation in 20 years. Valuation Summary We value Aerie based on the NPV of the cash flows associated with its glaucoma drug candidates. Our price target is $86/share." (10/2/2018)
Has Aerie Pharmaceuticals been receiving favorable news coverage?
News articles about AERI stock have been trending somewhat negative this week, according to InfoTrie. The research firm scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aerie Pharmaceuticals earned a news impact score of -1.7 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near future.
Who are some of Aerie Pharmaceuticals' key competitors?
Some companies that are related to Aerie Pharmaceuticals include argenx (ARGX), Allogene Therapeutics (ALLO), Ablynx (ABLYF), China Biologic Products (CBPO), Repligen (RGEN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Acceleron Pharma (XLRN), Spark Therapeutics (ONCE), Atara Biotherapeutics (ATRA), Crispr Therapeutics (CRSP), Regenxbio (RGNX), Alector (ALEC), Orchard Therapeutics (ORTX) and Momenta Pharmaceuticals (MNTA).
Who are Aerie Pharmaceuticals' key executives?
Aerie Pharmaceuticals' management team includes the folowing people:
- Dr. Vicente J. Anido Jr., CEO & Chairman (Age 65)
- Mr. Thomas A. Mitro, Pres & COO (Age 60)
- Dr. Casey C. Kopczynski, Co-Founder & Chief Scientific Officer (Age 57)
- Mr. Richard James Rubino CPA, CFO, Sec. & Treasurer (Age 60)
- Ms. Jessica Crespo CPA, Director of Accounting
Who are Aerie Pharmaceuticals' major shareholders?
Aerie Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.06%), Foresite Capital Management III LLC (4.29%), Partner Fund Management L.P. (4.17%), Foresite Capital Management II LLC (3.68%), Bank of New York Mellon Corp (3.23%) and Jennison Associates LLC (2.60%). Company insiders that own Aerie Pharmaceuticals stock include Casey C Kopczynski, Foresite Capital Fund Ii, LP, Gerald D Cagle, Richard J Rubino, Thomas A Mitro and Vicente Anido Jr. View Institutional Ownership Trends for Aerie Pharmaceuticals.
Which major investors are selling Aerie Pharmaceuticals stock?
AERI stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Partner Fund Management L.P., Orbimed Advisors LLC, Millennium Management LLC, Jennison Associates LLC, Columbus Circle Investors, Citigroup Inc. and Polar Capital LLP. Company insiders that have sold Aerie Pharmaceuticals company stock in the last year include Casey C Kopczynski, Richard J Rubino, Thomas A Mitro and Vicente Anido Jr. View Insider Buying and Selling for Aerie Pharmaceuticals.
Which major investors are buying Aerie Pharmaceuticals stock?
AERI stock was acquired by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Sectoral Asset Management Inc, Foresite Capital Management IV LLC, Foresite Capital Management III LLC, Foresite Capital Management II LLC, Candriam Luxembourg S.C.A., Eversept Partners LP and Rhenman & Partners Asset Management AB. View Insider Buying and Selling for Aerie Pharmaceuticals.
How do I buy shares of Aerie Pharmaceuticals?
Shares of AERI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aerie Pharmaceuticals' stock price today?
One share of AERI stock can currently be purchased for approximately $39.03.
How big of a company is Aerie Pharmaceuticals?
Aerie Pharmaceuticals has a market capitalization of $1.77 billion. The company earns $-145,100,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. Aerie Pharmaceuticals employs 160 workers across the globe.
What is Aerie Pharmaceuticals' official website?
How can I contact Aerie Pharmaceuticals?
Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The company can be reached via phone at 919-237-5300 or via email at [email protected]
MarketBeat Community Rating for Aerie Pharmaceuticals (NASDAQ AERI)
MarketBeat's community ratings are surveys of what our community members think about Aerie Pharmaceuticals and other stocks. Vote "Outperform" if you believe AERI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AERI will underperform the S&P 500 over the long term. You may vote once every thirty days.
